Article Data

  • Views 570
  • Dowloads 148

Original Research

Open Access

Sufentanil inhibits the invasion and epithelial-mesenchymal transition of endometrial cancer cells in vitro

  • Hongxia Chen1,†
  • Guangquan He2,†
  • Qin Gao1,*,

1Department of Anesthesiology, Affiliated Hospital of North Sichuan Medical College, 637000 Nanchong, Sichuan, China

2Department of Anesthesiology, Nanchong Central Hospital, 637000 Nanchong, Sichuan, China

DOI: 10.22514/ejgo.2024.033 Vol.45,Issue 2,April 2024 pp.112-117

Submitted: 01 November 2023 Accepted: 13 December 2023

Published: 15 April 2024

*Corresponding Author(s): Qin Gao E-mail: gaoqin3110101@163.com

† These authors contributed equally.

Abstract

This study investigates the impact of sufentanil on endometrial cancer (EC) cells. Human EC cell lines (HEC-1A and Ishikawa) were exposed to different concentrations (10, 20 and 40 nM) of sufentanil for 48 hours, following which cell-counting-kit 8 (CCK8), clone formation and transwell assays as well as and western blot were conducted. The findings revealed that sufentanil reduced the cell viability, colony formation, migration and invasion of both HEC-1A and Ishikawa cells. Moreover, sufentanil treatment resulted in decreased levels of matrix metallo proteinase 9 (MMP-9), MMP-2, N-cadherin and alpha smooth muscle actin (α-SMA) proteins while increasing the expression of E-cadherin in treated cells. Furthermore, sufentanil treatment was associated with decreased phosphorylation of phosphatidylinositol 3-kinase (PI3K), Akt and mammalian target of rapamycin (mTOR), suggesting that its inhibitory effects on the proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) of EC cells could be attributed to the inactivation of the PI3K/Akt/mTOR pathway.


Keywords

Endometrial cancer; Sufentanil; PI3K/Akt/mTOR pathway; Migration; Invasion; EMT


Cite and Share

Hongxia Chen,Guangquan He,Qin Gao. Sufentanil inhibits the invasion and epithelial-mesenchymal transition of endometrial cancer cells in vitro. European Journal of Gynaecological Oncology. 2024. 45(2);112-117.

References

[1] Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, et al. Endometrial cancer. Nature Reviews Disease Primers. 2021; 7: 88.

[2] van den Heerik ASVM, Horeweg N, de Boer SM, Bosse T, Creutzberg CL. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy. International Journal of Gynecological Cancer. 2021; 31: 594–604.

[3] Paderno M, Grassi T, Adorni M, Zambetti B, Martino GD, Bazzurini L, et al. Adjuvant treatment in endometrial cancer: when and what to choose. European Journal of Gynaecological Oncology. 2022; 43: 123–131.

[4] Yen T, Wang T, Fader AN, Shih I, Gaillard S. Molecular classification and emerging targeted therapy in endometrial cancer. International Journal of Gynecological Pathology. 2020; 39: 26–35.

[5] Marín-Jiménez JA, García-Mulero S, Matías-Guiu X, Piulats JM. Facts and hopes in immunotherapy of endometrial cancer. Clinical Cancer Research. 2022; 28: 4849–4860.

[6] Mittal V. Epithelial mesenchymal transition in tumor metastasis. Annual Review of Pathology. 2018; 13: 395–412.

[7] Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Science Signaling. 2014; 7: re8.

[8] Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nature Reviews Molecular Cell Biology. 2019; 20: 69–84.

[9] Connolly C, Madden SF, Buggy DJ, Gallagher HC. Expression of anaesthetic and analgesic drug target genes in excised breast tumour tissue: association with clinical disease recurrence or metastasis. PLOS ONE. 2017; 12: e0177105.

[10] Chen H, Zhu XM, Luo ZL, Hu YJ, Cai XC, Gu QH. Sevoflurane induction alleviates the progression of gastric cancer by upregulating the miR-34a/TGIF2 axis. European Review for Medical and Pharmacological Sciences. 2020; 24: 11883–11890.

[11] Maciejewski D. Sufentanil in anaesthesiology and intensive therapy. Anaesthesiology Intensive Therapy. 2012; 44: 35–41.

[12] Guan M, Huang Y, Lin X. Sufentanil inhibits the proliferation and epithelial mesenchymal transition of lung cancer cells through Wnt/beta-catenin signaling pathway. Bioengineered. 2022; 13: 10857–10865.

[13] Tang H, Li C, Wang Y, Deng L. Sufentanil inhibits the proliferation and metastasis of esophageal cancer by inhibiting the NF-κB and snail signaling pathways. Journal of Oncology. 2021; 2021: 7586100.

[14] Li M, Gu K, Kong Q, Wang G, Gu J. Sufentanil inhibits the metastasis and immune response of breast cancer via mediating the NF-κB pathway. Immunopharmacology and Immunotoxicology. 2023; 45: 663–671.

[15] Cai Y, Wang B, Xu W, Liu K, Gao Y, Guo C, et al. Endometrial cancer: genetic, metabolic characteristics, therapeutic strategies and nanomedicine. Current Medicinal Chemistry. 2021; 28: 8755–8781.

[16] Li Y, Yang S, Wang P. Molecular pathology and prognosis of endometrial cancer. Taiwanese Journal of Obstetrics and Gynecology. 2022; 61: 921–922.

[17] Tronconi F, Nero C, Giudice E, Salutari V, Musacchio L, Ricci C, et al. Advanced and recurrent endometrial cancer: state of the art and future perspectives. Critical Reviews in Oncology/Hematology. 2022; 180: 103851.

[18] Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends in Cell Biology. 2019; 29: 212–226.

[19] Liu J, Cui G, Shen S, Gao F, Zhu H, Xu Y. Establishing a prognostic signature based on epithelial-mesenchymal transition-related genes for endometrial cancer patients. Frontiers in Immunology. 2022; 12: 805883.

[20] Niland S, Riscanevo AX, Eble JA. Matrix Metalloproteinases shape the tumor microenvironment in cancer progression. International Journal of Molecular Sciences. 2021; 23: 146.

[21] Song Z, Wang J, Su Q, Luan M, Chen X, Xu X. The role of MMP-2 and MMP-9 in the metastasis and development of hypopharyngeal carcinoma. Brazilian Journal of Otorhinolaryngology. 2021; 87: 521–528.

[22] Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochimica Et Biophysica Acta (BBA)—Reviews on Cancer. 2012; 1825: 29–36.

[23] Langers AMJ, Verspaget HW, Hawinkels LJAC, Kubben FJGM, van Duijn W, van der Reijden JJ, et al. MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients. British Journal of Cancer. 2012; 106: 1495–1498.

[24] Tewari D, Patni P, Bishayee A, Sah AN, Bishayee A. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: a novel therapeutic strategy. Seminars in Cancer Biology. 2022; 80: 1–17.

[25] Jin Y, Sun L, Liu KC. Effect of sufentanil on the viability and apoptosis of cervical cancer cells via the inactivation of PI3K/AKT/mTOR signaling pathway. European Journal of Gynaecological Oncology. 2021; 42: 325–332.

[26] Pavlidou A, Vlahos NF. Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer. The Scientific World Journal. 2014; 2014: 709736.

[27] Barra F, Evangelisti G, Ferro Desideri L, Di Domenico S, Ferraioli D, Vellone VG, et al. Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer. Expert Opinion on Investigational Drugs. 2019; 28: 131–142.

[28] Roncolato F, Lindemann K, Willson ML, Martyn J, Mileshkin L. PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. Cochrane Database of Systematic Reviews. 2019; 10: CD012160.

[29] Qu J, Sun Y, Yang L, Niu X, Li L. Fucoxanthin prevents cell growth and induces apoptosis in endometrial cancer HEC-1A cells by the inhibition of the PI3K/Akt/mTOR pathway. Journal of Biochemical and Molecular Toxicology. 2022; 36: e23027.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top